The estimated Net Worth of Arthur M Krieg is at least 8.57 百万$ dollars as of 18 June 2021. Dr Krieg owns over 7,224 units of Checkmate Pharmaceuticals stock worth over 8,565,207$ and over the last 11 years he sold CMPI stock worth over 0$. In addition, he makes 0$ as Founder、 Chief Scientific Officer、 Treasurer、 Sec. & Independent Director at Checkmate Pharmaceuticals.
Dr has made over 10 trades of the Checkmate Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 7,224 units of CMPI stock worth 43,633$ on 18 June 2021.
The largest trade he's ever made was buying 33,220 units of Checkmate Pharmaceuticals stock on 29 March 2021 worth over 370,735$. On average, Dr trades about 7,928 units every 15 days since 2014. As of 18 June 2021 he still owns at least 815,734 units of Checkmate Pharmaceuticals stock.
You can see the complete history of Dr Krieg stock trades at the bottom of the page.
Dr. Arthur M. Krieg is the Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director at Checkmate Pharmaceuticals.
Dr Krieg is 64, he's been the Founder、 Chief Scientific Officer、 Treasurer、 Sec. & Independent Director of Checkmate Pharmaceuticals since . There are no older and 4 younger executives at Checkmate Pharmaceuticals.
Arthur's mailing address filed with the SEC is C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Checkmate Pharmaceuticals have traded over 15,801,789$ worth of Checkmate Pharmaceuticals stock and bought 928,470 units worth 13,457,615$ . The most active insiders traders include Holdings A/S Novo、Global Strategic Fund Ii L....、Michael Powell. On average, Checkmate Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of 1,077,132$. The most recent stock trade was executed by Global Strategic Fund Ii L.... on 13 May 2022, trading 131,650 units of CMPI stock currently worth 1,375,743$.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Checkmate Pharmaceuticals executives and other stock owners filed with the SEC include: